Immatics N.V. Stock: price and insider trades · United States
1 insider bought €6.4M of shares over the last 90 days, the latest by PERCEPTIVE ADVISORS LLC, filed 27 Aug 2026.
Immatics N.V.: what insiders have been doing
Only a handful of insider records exist for Immatics N.V., the last one from 27 August 2026, too few to describe a trend. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Key facts
Headquarters: Tübingen, Germany · Founded: 2000
Source: Wikidata (CC0).
Who traded when
BuySaleSince the insiders bought
- -10.1%Entry US$9.45 · Close at T+30 US$8.50
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate Immatics N.V. Strong Buy (bullish), based on 7 analysts. Average price target: US$17.26.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended December 2025 · cache
- 863,060 shares@ US$8.690.58% mcap100.0% of flowOrdinary SharesSEC:0001193125-26-371237:0Canonical exit: 24 Nov 2026 (T+90)
1 of 1 declaration
About Immatics N.V.
Immatics N.V. is a biopharmaceutical company focused on developing therapies based on tumor targets. It specializes in innovation in cancer treatment using advanced technologies.
Recent ranked signals on the same market
Purchases our model currently ranks for the recommendations list.
All recommendations
